The EMI will advertise ‘Expressions of Interest’ (EoI) calls twice a year in February and August to gather interest from prospective academics and industry partners. To be eligible, all EoIs need to have an industry partner and secured funding for the clinical project. If either party does not yet have a collaboration they’re invited to get in touch at their earliest convenience (Email Dr. Mellone Marchong) so that mutual interest could be appropriately matched to academics or industry scientists. Once all eligible EoIs have been approved by the EMI Steering Committee, each Industry Partner will meet with the Director of the EMI to decide which project(s) they will fund. This decision will typically depend on the below criteria:
- Secured collaboration and funding for the project with an Industry Partner
- Area of research is spread equally across all posts for the current year
- Projects meet the strategic interest of both the Industry Partner and the EMI scheme
- Projects are advanced enough to be deliverable within the timeframes
Suitable industry collaborations projects include:
- Design and conduct of challenge studies in human healthy volunteers or patients with tool compounds for purposes of understanding the role of particular pathways in human pathophysiology
- Characterization of ex vivo responses of blood and tissue samples from genotyped individuals for purposes of understanding the effects of genetic polymorphism on response to AZ/MedI/GSK compounds in development
- Development of biomarker methodology (including imaging) for use in clinical trials
- Development of systems biology models integrating PK and PD data for modelling and simulation of trial outcomes
Shortly after the EoI calls, information regarding recruitment for PhD positions or Clinical Lectureships will be advertised on GCAT website. Details regarding Senior Experimental Medicine Investigators and Post-Doctoral Clinical Scientists Posts can be found on the EMIT website.
NOTE: Recruitment for all EMI Posts will be managed by the GCAT Office.
These will be 3-year posts, with an additional 6-month taught component for those who have not completed the MPhil, which will equip students with the scientific and regulatory knowledge required to undertake Experimental Medicine studies in man.
Students will cover the following modules from the new MPhil in Clinical Science and specialist training in Clinical Pharmacology: Practical Aspects of Clinical Research; Basic Pharmacology; Pharmacokinetics; Toxicology; Clinical Drug Development; and Medical Statistics.
PhD projects will be developed jointly by industry and academic partners and should include at least one Experimental Medicine study involving giving a drug/or challenge agent to human subjects. Other components may include mechanistic, laboratory-based analyses, and biomarker discovery/development/validation.
There is an option to spend up to a year based with the industrial partner, or other Departments within the University. All students will have joint University and industry partner supervisors and a separate academic mentor.
To see current PhD post click here.
Academic Clinical Lecturer Posts
These will be 4-year posts and the research focus will be of significant joint interest by the University and Industry Partner and have a strong emphasis on human studies or clinical trials. The EMI Scheme will fund 50% of the ACL base salary. The host Department must have identified the remaining 50% funding and any on-call supplement. The project funds must be sourced by either the academic or industry partner. Applicants must also have confirmation from the training programme director (TPD) that there is a free national training number (NTN) for the successful candidate to take up.
PIs who would like to create a joint post with Clinical Pharmacology, please discuss with Dr. Kevin O’Shaughnessey in the first instance (Email Kevin O’Shaughnessy).
For further information on creating an ACL post or to answer any queries, please contact Ann Enticknap, Clinical Academic Programme Manager, GCAT.
Current ACL posts will be advertised in due course.
Step 1: For Cambridge PIs who do not yet have an Industry Partner contact
Please review the EoI proformas and eligibility to see if your research might qualify. It should be a clinical trial type study. AstraZeneca/MedImmune’s key areas of interest include cardiovascular, immunological, metabolic, oncological and respiratory medicine. GSK R&D’s key areas of strategic interest include respiratory, immuno-inflammation, oncology, vaccines, HIV/infectious diseases and rare diseases. Cambridge PIs who are interested in a collaboration with AstraZeneca/MedImmune or GSK are asked to email Dr. Mellone Marchong to discuss further. Your email should include Cambridge PI details, Industry Partner area of interest, Cambridge PI area of interest/expertise or project idea. Where there is mutual interest, Industry Partners and Cambridge leads will be matched to enable project development. This process typically takes approximately 6 months to 1 year. The project needs to have significant Industry Partner input.
Step 2: For Cambridge PIs who already have an Industry Partner collaborator/contact
Step 3: Funding Decision
Eligible EoIs will be reviewed by the EMI Steering Committee. Once approved, the Individual Industry Partners and EMI Director will meet separately to select which projects they would like to take forward.